Do we Need New Therapies for Diabetes?

Dimiter Dimitrov*

Do we Need New Therapies for Diabetes?

Diabetes research and practice cluster often question the need of new therapies.
Why would we need new therapies nowadays, when we have 9 classes, rapidly increasing
number of biosimilars2 and uncountable number of generics? Reasonable question.

Does it make sense to invest billions of dollars in messy global cardiovascular outcomes
trials or to play love attraction games with payers so they “fall in love” with the “new”
pill.

Well….I believe someone is missing in this picture. Obviously, those four players
forget the Patient. And the ability to ask a bit more simple and rational questions, such as “Do
we have adequate glycemic control of diabetes in the presence of all those therapies”?

I know that such question would add “noise” in the discussion from the different
parties returning back the ball to the patients, who do not have proper life style and as well as
knowledge on the condition.

To avoid entering a philosophical thoughtfulness that we do not live a perfect world,
I will answer directly the main question of this Opinion. Yes, we desperately need breakthrough
therapies for diabetes. Not therapies that mimic the current ones. We need therapies that do not complicate the natural way of thinking by adding the next complex scheme.

Diabetes Res Open J. 2015; 1(3): 75-76. doi: 10.17140/DROJ-1-112

LATEST ARTICLES

 - 
Arabic
 - 
ar
Bengali
 - 
bn
German
 - 
de
English
 - 
en
French
 - 
fr
Hindi
 - 
hi
Indonesian
 - 
id
Portuguese
 - 
pt
Russian
 - 
ru
Spanish
 - 
es